Fibrosis News and Research

RSS

Fibrosis is the growth of fibrous tissue.

Hydrogen sulfide decreases manufacture of kidney scarring matrix proteins

Hydrogen sulfide, a gas notorious for its rotten-egg smell, may have redeeming qualities after all. It reduces high glucose-induced production of scarring proteins in kidney cells, researchers from The University of Texas Health Science Center San Antonio report in the Journal of Biological Chemistry.

4 Jan 2012

UCSF professor receives 2012 Paul Ehrlich and Ludwig Darmstaedter Prize

Peter Walter, PhD, a professor in the Biochemistry and Biophysics Department within the School of Medicine at the University of California, San Francisco has been awarded the 2012 Paul Ehrlich and Ludwig Darmstaedter Prize for his "outstanding research achievements in the field of cell biology."

26 Dec 2011

ViroPharma to acquire Meritage

ViroPharma Incorporated today announced that it has entered into an exclusive option to acquire Meritage Pharma, Inc., a private company based in San Diego, CA focused on developing oral budesonide suspension (OBS) as a treatment for eosinophilic esophagitis (EoE), a chronic inflammatory disorder of the esophagus.

23 Dec 2011

Researchers identify second oldest human disease mutation

A new study has identified a gene mutation that researchers estimate dates back to 11,600 B.C., making it the second oldest human disease mutation yet discovered.

16 Dec 2011

IQWiG publishes report on Esbriet benefit assessment for treatment of IPF

InterMune, Inc. today reported that the private Institute for Quality and Efficiency in Health Care (IQWiG) has today published its report on the benefit assessment of Esbriet (pirfenidone) for the treatment of mild to moderate idiopathic pulmonary fibrosis.

16 Dec 2011

FDA accepts Vertex KALYDECO NDA for six-month Priority Review

Vertex Pharmaceuticals Incorporated announced today that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for KALYDECOTM (ivacaftor) and granted the company's request for six-month Priority Review.

16 Dec 2011

Liver transplantations for NASH-Cirrhosis increase dramatically

Nonalcoholic steatohepatitis (NASH) occurs when fat builds up in the liver. This accumulation of fat damages the liver and leads to cirrhosis. NASH is rapidly increasing in the U.S. mainly related to the epidemics of obesity and diabetes.

15 Dec 2011

Gene therapy can reduce painful bleeding episodes in patients with hemophilia B

Symptoms improved significantly in adults with the bleeding disorder hemophilia B following a single treatment with gene therapy developed by researchers at St. Jude Children's Research Hospital in Memphis and demonstrated to be safe in a clinical trial conducted at the University College London (UCL) in the U.K.

12 Dec 2011

Alios BioPharma, Vertex initiate ALS-2200 and ALS-2158 clinical study in HCV

Vertex Pharmaceuticals Incorporated and Alios BioPharma, Inc. today announced the initiation of two clinical studies for the nucleotide analogues ALS-2200 and ALS-2158, which are inhibitors of the hepatitis C NS5B polymerase.

12 Dec 2011

Galectin Therapeutics to initiate GM-CT-01 Phase 1/2 combination study in advanced MM

Galectin Therapeutics, the Cancer Centre at the Cliniques universitaires Saint-Luc and the Ludwig Institute for Cancer Research (LICR) announced today that they will initiate a Phase 1/2 safety and efficacy trial testing a novel treatment combination in patients with advanced metastatic melanoma.

9 Dec 2011

Israeli Nobel Laureate receives AvH's Humboldt Research Award

The Israeli Nobel Laureate Aaron Ciechanover has been named one of the recipients of the Humboldt Research Award of the Alexander von Humboldt Foundation.

8 Dec 2011

Positive results from Pearl Therapeutics' PT001 Phase 2b trial on COPD

Pearl Therapeutics Inc. today announced positive top-line results from a randomized, double-blind, Phase 2b, dose-ranging study of glycopyrrolate, a long-acting muscarinic agonist (LAMA) delivered twice a day (BID) via metered-dose inhaler in patients with moderate-to-severe COPD.

8 Dec 2011

Relaxin improves poor blood flow and kidney function in a rat model of PKD

After a four-week course of the vasodilator hormone relaxin, kidney function and blood flow immediately improved in lab rats genetically altered to model polycystic kidney disease (PKD), a life-threatening genetic disorder, according to research presented on Dec. 6 at the American Society for Cell Biology Annual Meeting in Denver.

7 Dec 2011

New NHGRI funding plan sharpens focus of Genome Sequencing Program on medical apps

A new funding plan by the National Human Genome Research Institute (NHGRI) sharpens the focus of its flagship Genome Sequencing Program on medical applications. In addition to continuing on-going studies, the four-year, $416 million plan launches new efforts to find causes of rare inherited diseases and accelerate the use of genome sequence information in the medical care of patients.

7 Dec 2011

FDA modifies requirements of Amgen's Nplate REMS Program

Amgen today announced the U.S. Food and Drug Administration (FDA) has modified the requirements of the Nplate (romiplostim) Risk Evaluation and Mitigation Strategy (REMS) Program.

7 Dec 2011

Towards a national plan of action for rare diseases

"Rare diseases", by their very definition, occur in no more than 5 people out of every 10,000 inhabitants. Barely noticed by the general public, only around 1,000 of the currently 6,000 or so different rare diseases currently listed on the Internet platform Orphanet are treatable nowadays.

5 Dec 2011

Mainz gastroenterologist awarded ERC Advanced Grant

The European Research Council (ERC) has earmarked about €2.5 mio. to fund the research being conducted by gastroenterologist and biochemist Professor Dr. Dr. Detlef Schuppan at Mainz University Medical Center.

3 Dec 2011

Pfizer acquires Excaliard

Pfizer Inc. announced today that it has completed its acquisition of Excaliard Pharmaceuticals, Inc., a privately owned biopharmaceutical company focused on developing novel drugs for the treatment of skin fibrosis, more commonly referred to as skin scarring.

3 Dec 2011

Baby boomers more likely to develop HCV

Experts at Montefiore Medical Center urge the general public to be tested for the Hepatitis C virus, especially baby boomers, adults born between 1946-1964, who could be most at risk for this disease. Baby boomers are more likely to have been exposed to dangerous risk factors decades ago, such as sharing a drug needle, being tattooed or pierced with unsterilized tools or receiving a tainted blood transfusion.

2 Dec 2011

Doctors underestimate worldwide burden of CPA, says public health expert

Researchers have discovered that over a million people worldwide diagnosed with TB go on to develop an incurable but manageable fungal infection which is usually left untreated because it is mistaken for a recurrence of the disease.

2 Dec 2011